Biomarkers and potential targets for immune and cellular therapy in triple negative breast cancer

Molchanov, O. A.; Maistrenko, Dmitrii; Granov, Dmitrii; Vasina, Lubov; Popova, Alena; Vasilevskaya, Irina A.; Mikolaichuk, Olga; Shemchuk, Olga; Popova, E.; Protas, Alexandra; Sharoyko, Vladimir V.; Semenov, Konstantin N.

doi:10.18620/ctt-1866-8836-2022-11-2-16-30

Cited by 2 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…JAK киназы активируются при лиганд-рецепторном взаимодействии различных цитокинов (IL-6, IL-11, IL-27, IL-31), хемокинов (IL-8, CXCR12, CXCR7), факторов роста (TGF-b, EGF, IGF, PDGF-C), пептидных гормонов (гастрин). Под действием цитокинов и факторов роста (IL-6, IL-8, TGF-b, IGF, EGF) происходит активация комплекса JAK/STAT3, который стимулирует экспрессию ряда генов, обеспечивающих EMT [16,20,31].…”

unclassified

Theranostics of triple negative breast cancer: a review

Molchanov

Maystrenko

Stanzhevsky

2023

Lučevaâ diagn. ter.

View full text Add to dashboard Cite

INTRODUCTION: Triple negative cancer is one of the most aggressive subtypes of breast cancer. Currently, no effective treatment methods have been proposed that would significantly affect the long-term results of treatment.OBJECTIVE: To summarize the possibilities of theranostics and nanteranostics in the visualization and elimination of malignant cells and immunosuppressive cells of the microenvironment of thriple negative breast cancer.MATERIALS AND METHODS: A search was conducted for scientific publications in the PubMed information and analytical system for 2015–2022 by keywords: «triple negative breast cancer» («triple negative breast cancer»), «signaling pathways» («signaling pathways»), «tumor microenvironment» («tumor microenvironment»), «cancer stem cells» («stem tumor cells»), «theranostics», «nanomaterials» («nanomaterials»), «nanotheranostics» («nanoteranostics»). After excluding articles devoted to the technical aspects of molecular biological research, 57 publications related to the theranostics of thrice-negative breast cancer were analyzed.RESULTS: Targets for theranostics of triple negative breast cancer are associated with tumor cells and components of the microenvironment. The article presents data on the composition and interaction between various cellular subpopulations in the tumor microenvironment, as well as on the role of cancer stem cells in its formation. State of art classifications of triple negative breast cancer and data on molecular defects associated with various subtypes are presented. Targets for theranostics associated with stem, differentiated tumor cells and components of the tumor microenvironment are described. The authors present their own data on the nature of the distribution of various subpopulations of the microenvironment, which should be taken into account when choosing the nature of the effect on the tumor. The possibilities and applications of radiopharmaceuticals and nanoparticle-based preparations developed to date have been analyzed.CONCLUSION: Triple negative breast cancer is characterized by the presence of a large number of biomarkers that can be targets for diagnostic and therapeutic drugs. It is advisable to use artificial intelligence technologies for their selection. The use of nanoparticles makes it possible to reduce toxicity and ensure the implementation of several treatment methods simultaneously.

show abstract

unclassified

Theranostics of triple negative breast cancer: a review

Molchanov

Maystrenko

Stanzhevsky

2023

Lučevaâ diagn. ter.

View full text Add to dashboard Cite

show abstract

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

Balahura

Dinescu

Costache

2023

IJMS

View full text Add to dashboard Cite

During the past decade, researchers have investigated the molecular mechanisms of breast cancer initiation and progression, especially triple-negative breast cancer (TNBC), in order to identify specific biomarkers that could serve as feasible targets for innovative therapeutic strategies development. TNBC is characterized by a dynamic and aggressive nature, due to the absence of estrogen, progesterone and human epidermal growth factor 2 receptors. TNBC progression is associated with the dysregulation of nucleotide-binding oligomerization domain-like receptor and pyrin domain-containing protein 3 (NLRP3) inflammasome, followed by the release of pro-inflammatory cytokines and caspase-1 dependent cell death, termed pyroptosis. The heterogeneity of the breast tumor microenvironment triggers the interest of non-coding RNAs’ involvement in NLRP3 inflammasome assembly, TNBC progression and metastasis. Non-coding RNAs are paramount regulators of carcinogenesis and inflammasome pathways, which could help in the development of efficient treatments. This review aims to highlight the contribution of non-coding RNAs that support inflammasome activation and TNBC progression, pointing up their potential for clinical applications as biomarkers for diagnosis and therapy.

show abstract

Biomarkers and potential targets for immune and cellular therapy in triple negative breast cancer

Cited by 2 publications

References 69 publications

Theranostics of triple negative breast cancer: a review

Theranostics of triple negative breast cancer: a review

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

Contact Info

Product

Resources

About